Drug Trial Radar · NCT06090422
Ketamine for Combined Depression and Alcohol Use Disorder
Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
34
Planned (sponsor's estimate)
Start
Jan 20, 2025
Primary completion
Jul 1, 2028
Study completion Jul 1, 2028
Sponsor
- Lead sponsor
- University Hospital of North NorwayAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- University of Exeter; Ostfold Hospital Trust
- First posted
- Oct 19, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to investigate the effects of ketamine, in combination with standard inpatient addiction therapy, for adults with depression and alcohol use disorder. After screening and enrollment, participants will undergo baseline assessments of depression, measures of alcohol use and craving, as well as neurocognitive function. Participants will then be randomized to either ketamine (intervention) or midazolam (control). All participants will be admitted for standard inpatient addiction therapy while receiving ketamine or midazolam. Measures on safety, depression and alcohol use disorder will be repeatedly assessed during and after treatment. Final follow-up assessment is scheduled 6 months after baseline assessment.
Conditions
- Depression
- Alcohol Use Disorder
Interventions
Ketamine HydrochlorideDrug
Four single-doses, given two times per week for two weeks Dose: 0,8 mg/kg body weight Route of administration: intravenous infusions over 40 minutes
Midazolam HydrochlorideDrug
Four single-doses, given two times per week for two weeks Dose: 0,02 mg/kg body weight Route of administration: intravenous infusions over 40 minutes
Primary outcomes
What the sponsor says the trial is designed to measure.
- DepressionTime frame: Within 3 days after final treatment session
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Department of Addiction Treatment, ØHT
Moss, Norway · Not yet recruiting
Department of Addiction, University Hospital of North Norway
Tromsø, Norway · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.